Evidence map›Paper›PMID 36747259›Full record

ArticleFungal biology and biotechnology2023

Biocontrol of Fusarium equiseti using chitosan nanoparticles combined with Trichoderma longibrachiatum and Penicillium polonicum.

El-Sayed M El-Morsy, Yomna S Elmalahy, Mohamed M A Mousa

Open access · goldAbstract read
In one paragraph

Article in Fungal biology and biotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Pathogens (Basel, Switzerland) · 2025
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Nanoplatforms for the Delivery of Nucleic Acids into Plant Cells.International journal of molecular sciences · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

El-Sayed M El-MorsyBotany and Microbiology Department, Faculty of Science, Damietta University, New Damietta, 34517, Egypt.
Yomna S ElmalahyBotany and Microbiology Department, Faculty of Science, Damietta University, New Damietta, 34517, Egypt. youmnael.malahy@du.edu.eg.
Mohamed M A MousaBotany and Microbiology Department, Faculty of Science, Damietta University, New Damietta, 34517, Egypt.
Damietta University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A safe and ecofriendly biocontrol of pathogenic Fusarium equiseti was developed based on chitosan nanoparticles (CNPs) combined with Trichoderma longibrachiatum and Penicillium polonicum. Two strains of F. equiseti which were isolated from wilting tomato plant as well as three antagonistic fungi including Trichoderma longibrachiatum and two strains of Penicillium polonicum were isolated from the surrounding soil. All the isolated pathogenic and antagonistic fungi were identified using genomic DNA sequences. The antifungal activity of the three antagonistic fungi were studied against the two strains of F. equiseti. Also, CNPs which were prepared according to the ionic gelation method using sodium tripolyphosphate anions in acetic acid solution were used to enhance the antifungal activity of the three antagonistic fungi. The results exhibit that, combination of T. longibrachiatum with CNPs and P. polonicum with CNPs achieve high antifungal activity against F. equiseti by an inhibition rate equal to 71.05% and 66.7%, respectively.

Indexed as

Antagonistic fungiAntifungalChitosan nanoparticlesFusarium equisetiPathogenic fungi

Identifiers

PMID36747259
PMCPMC9903466
OpenAlexW4319304410

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.